Evidence map›Paper›PMID 31888883›Full record

Trial reportDiabetes care2020

Vasodilatory Actions of Glucagon-Like Peptide 1 Are Preserved in Skeletal and Cardiac Muscle Microvasculature but Not in Conduit Artery in Obese Humans With Vascular Insulin Resistance.

Nasui Wang, Alvin W K Tan, Linda A Jahn, Lee Hartline, James T Patrie, Shaoda Lin, Eugene J Barrett, Kevin W Aylor, Zhenqi Liu

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05478707 (Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes), which is not on this map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05478707 phase2recruitingstarted 2023, after this paper: background citation

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

Ran2023Enrolled47Registered outcomes5Posted comparisons0ConditionsDiabetes Mellitus, Type 1, Endothelial DysfunctionArmsDulaglutide, Placebo
PMID 29310645PMID 24742660PMID 22732108PMID 27295427PMID 27436611PMID 27633186PMID 33219433PMID 33259257PMID 34075130PMID 34339111PMID 9490243PMID 30291013other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Review
  10. Observational
  11. Review
  12. Muscle health in the modern era of incretin-based therapies.European journal of clinical investigation · 2026
    Review
  13. Review
  14. Review
  15. Targeting Sarcopenia in CKD: The Emerging Role of GLP-1 Receptor Agonists.International journal of molecular sciences · 2025
    Review
  16. Review
  17. Review
  18. Review
  19. Metabolic Reprogramming in Heart Failure: From Energy Starvation to Therapeutic Targets.Current treatment options in cardiovascular medicine · 2025
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 3 countries.

Nasui WangDivision of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville, VA.
Alvin W K TanDivision of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville, VA.
Linda A JahnDivision of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville, VA.
Lee HartlineDivision of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville, VA.
James T PatrieDepartment of Public Health Sciences, University of Virginia Health System, Charlottesville, VA.
Shaoda LinDepartment of Endocrinology and Metabolism, Shantou University First Hospital, Guangdong, China.
Eugene J BarrettDivision of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville, VA.ORCID 0000-0003-0689-4044
Kevin W AylorDivision of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville, VA.
Zhenqi LiuDivision of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville, VA zl3e@virginia.edu.ORCID 0000-0001-5077-0941
University of Virginia Health System · USShantou University · CN

Funding

Acute effects of hyperglycemia on heart and skeletal muscle microvasculatureR01HL142250 · NHLBI · UNIVERSITY OF VIRGINIA · PI EUGENE Joseph BARRETT · 2022 to 2022
$737k
NHLBI NIH HHS R01 HL094722NHLBI NIH HHS R01 HL142250NIDDK NIH HHS R01 DK102359
6 · The paper itself

Abstract

objectiveObesity is associated with microvascular insulin resistance, which is characterized by impaired insulin-mediated microvascular recruitment. Glucagon-like peptide 1 (GLP-1) recruits skeletal and cardiac muscle microvasculature, and this action is preserved in insulin-resistant rodents. We aimed to examine whether GLP-1 recruits microvasculature and improves the action of insulin in obese humans. RESEARCH DESIGN AND

methodsFifteen obese adults received intravenous infusion of either saline or GLP-1 (1.2 pmol/kg/min) for 150 min with or without a euglycemic insulin clamp (1 mU/kg/min) superimposed over the last 120 min. Skeletal and cardiac muscle microvascular blood volume (MBV), flow velocity and blood flow, brachial artery diameter and blood flow, and pulse wave velocity (PWV) were determined.

resultsInsulin failed to change MBV or flow in either skeletal or cardiac muscle, confirming the presence of microvascular insulin resistance. GLP-1 infusion alone increased MBV by ∼30% and ∼40% in skeletal and cardiac muscle, respectively, with no change in flow velocity, leading to a significant increase in microvascular blood flow in both skeletal and cardiac muscle. Superimposition of insulin to GLP-1 infusion did not further increase MBV or flow in either skeletal or cardiac muscle but raised the steady-state glucose infusion rate by ∼20%. Insulin, GLP-1, and GLP-1 + insulin infusion did not alter brachial artery diameter and blood flow or PWV. The vasodilatory actions of GLP-1 are preserved in both skeletal and cardiac muscle microvasculature, which may contribute to improving metabolic insulin responses and cardiovascular outcomes.

conclusionsIn obese humans with microvascular insulin resistance, GLP-1's vasodilatory actions are preserved in both skeletal and cardiac muscle microvasculature, which may contribute to improving metabolic insulin responses and cardiovascular outcomes.

Indexed as

Insulin ResistanceObesityAdministration, IntravenousAdultBlood GlucoseBrachial ArteryCoronary VesselsFemaleGlucagon-Like Peptide 1Glucose Clamp TechniqueHeartHumansMaleMicrovesselsMuscle, SkeletalMyocardiumBlood GlucoseGlucagon-Like Peptide 1Vasodilator Agents

Identifiers

PMID31888883
PMCPMC7035589
OpenAlexW2997074781

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.